Atlas Trials

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Clinical trial NCT06421298 · RECRUITING

Trial details

NCT number
NCT06421298
Sponsor
Jinghui Wang
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Lung Cancer
Start date
2024-05-17
Primary completion
2027-05-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.